# US 6,727,225 B2 · TWEAK receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,225 B2
- Document ID: US6727225B2
- Status: Granted
- Kind: B2
- Application number: 09/883,777
- Filed: 2001-06-18
- Published: 2002-08-15
- Granted: 2004-04-27
- Earliest claimed: 1999-12-20
- Assignees: Immunex Corporation
- Inventors: Steven R. Wiley
- Web page: https://patentgrep.com/patent/US6727225B2

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/73: containing coiled-coiled motif (leucine zippers)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.

## Claims

### Claim 1

An isolated polypeptide consisting of a sequence of amino acids that is at least 80% identical to a reference sequence of amino acids, wherein said reference sequence of amino acids consists of residue 28 to residue x1 of SEQ ID NO:4, x1 is selected from the group of residues 68 to 80 of SEQ ID NO:4, and said isolated polypeptide binds to TWEAK.

### Claim 2 (depends on 1)

The isolated polypeptide of claim 1 wherein said isolated polypeptide consists of a sequence of amino acids that is at least 90% identical to said reference sequence of amino acids.

### Claim 3 (depends on 2)

The isolated polypeptide of claim 2, wherein said isolated polypeptide consists of a sequence of amino acids that is at least 95% identical to said reference sequence of amino acids.

### Claim 4

An isolated polypeptide comprising a sequence Z1-X-Z2, wherein Z1 and Z2 each individually is a polypeptide consisting of a sequence of amino acids that is at least 80% identical to a reference sequence of amino acids, wherein said reference sequence of amino acids consists of residue 28 to residue x1 of SEQ ID NO:4, x1 is selected from the group of residues 68 to 80 of SEQ ID NO:4, X is a peptide linker, and said isolated polypeptide binds to TWEAK.

### Claim 5 (depends on 4)

The isolated polypeptide of claim 4, wherein said Z1 and Z2 each individually is a polypeptide consisting of a sequence of amino acids that is at least 90% identical to said reference sequence of amino acids.

### Claim 6 (depends on 4)

The isolated polypeptide of claim 4, wherein said Z1 and Z2 each individually is a polypeptide consisting of a sequence of amino acids that is at least 95% identical to said reference sequence of amino acids.

### Claim 7 (depends on 4)

The isolated polypeptide of claim 4, wherein Z1 and Z2 have the same amino acid sequence.

### Claim 8 (depends on 4)

The isolated polypeptide of claim 4 wherein X is selected from the group consisting of: —Gly—Gly—, GGGGS (SEQ ID NO: 10), (GGGGS)n (SEQ ID NO: 11), GKSSGSGSESKS (SEQ ID NO: 12), GSTSGSGKSSEGKG (SEQ ID NO:13), GSTSGSGKSSEGSGSTKG (SEQ ID NO:14), GSTSGSGKPGSGEGSTKG (SEQ ID NO:15), and EGKSSGSGSESKEF (SEQ ID NO:16).

### Claim 9 (depends on 1)

A fusion polypeptide comprising the polypeptide of claim 1 operably linked to a polypeptide of interest.

### Claim 10 (depends on 9)

The fusion polypeptide of claim 9, wherein the polypeptide of interest is an Fc polypeptide, leucine zipper polypeptide, or an peptide linker.
